Ascendis Pharma A/S (ASND) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ascendis Pharma A/S (ASND) has outperformed United Therapeutics (UTHR) over the past year, gaining 20.1% versus a gain of 16.8%. Over five years, UTHR leads with a +186.5% price change compared with +75.7% for ASND. United Therapeutics is the larger company by market cap ($23.63 billion vs $16.58 billion), about 1.4 times the size.
On valuation, United Therapeutics trades at a lower forward P/E (17.4x vs 20.5x for Ascendis Pharma A/S).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | UTHR |
|---|---|---|
| Share price | $252.73 | $554.73 |
| Market cap | $16.58B | $23.63B |
| 1-day change | -1.26% | -0.78% |
| YTD return | +18.52% | +13.85% |
| 1-year return | +20.07% | +16.83% |
| 5-year return | +75.73% | +186.47% |
| P/E ratio (TTM) | 16.62 | 20.94 |
| Forward P/E | 20.47 | 17.44 |
| EPS (TTM) | $15.21 | $26.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.18B |
| Revenue growth (YoY) | — | +10.61% |
| Net income (latest FY) | — | $1.33B |
| Gross margin | — | 87.92% |
| Operating margin | — | 46.89% |
| Net margin | — | 41.94% |
| 52-week high | $282.15 | $614.23 |
| 52-week low | $188.08 | $455.63 |
| Distance from 52-week high | -10.43% | -9.69% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +24.95% | +23.87% |
| Average volume | 750.65K | 702.78K |
| Shares outstanding | 65.60M | 42.59M |
| Employees | 1,189 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- United Therapeutics trades at a higher earnings multiple (20.9x vs 16.6x trailing P/E).
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
ASND vs UTHR FAQ
Which is bigger, Ascendis Pharma A/S or United Therapeutics?
United Therapeutics (UTHR) is larger, with a market capitalization of $23.63B compared with $16.58B for Ascendis Pharma A/S (ASND).
Which stock has performed better over the past year, ASND or UTHR?
ASND returned +20.07% over the past 12 months, compared with +16.83% for UTHR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASND or UTHR?
ASND has the lower trailing P/E at 16.6, versus 20.9 for UTHR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Ascendis Pharma A/S and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.